Inactive Instrument

Becton, Dickinson and Company Stock Nyse

Equities

BDXB

US0758874061

Medical Equipment, Supplies & Distribution

Sales 2024 * 20.25B 27.68B Sales 2025 * 21.47B 29.35B Capitalization 66.25B 90.55B
Net income 2024 * 2.09B 2.86B Net income 2025 * 2.48B 3.39B EV / Sales 2024 * 3.92 x
Net Debt 2024 * 13.13B 17.95B Net Debt 2025 * 10.8B 14.75B EV / Sales 2025 * 3.59 x
P/E ratio 2024 *
32.2 x
P/E ratio 2025 *
28.5 x
Employees 73,000
Yield 2024 *
1.64%
Yield 2025 *
1.68%
Free-Float 77.74%
More Fundamentals * Assessed data
Dynamic Chart
Evercore ISI Adjusts Price Target on Becton, Dickinson to $285 From $290, Maintains Outperform Rating MT
BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool CI
Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024 CI
Evercore ISI Raises Becton, Dickinson and Company's Price Target to $290 From $282 MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash DJ
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. CI
DBS Bank Adjusts Price Target on Becton, Dickinson to $285 From $300 MT
Transcript : Becton, Dickinson and Company Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
Exclusive-Biden to put tariffs on China medical supplies - sources RE
Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating MT
TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 MT
More news
Managers TitleAgeSince
Chief Executive Officer 50 08-12-31
Director of Finance/CFO 52 21-09-05
Chief Tech/Sci/R&D Officer 48 18-12-31
Members of the board TitleAgeSince
Director/Board Member 73 02-09-23
Director/Board Member 73 13-01-28
Director/Board Member 69 10-07-25
More insiders
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
Related indices
More about the company